Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

European approval for Valtropin

May 8, 2006

AstraZeneca discontinues development of Galida

May 8, 2006

AEterna Zentaris and U. of Montreal collaborate on ghrelin research

May 8, 2006

Novel agents for obesity and disorders of lipoprotein metabolism patented

May 5, 2006

FDA approves SPA for Puricase phase III trials

May 5, 2006

Diamyd Medical plans phase III study of Diamyd

May 5, 2006

GSK advances calcilytic compound from NPS collaboration

May 5, 2006

Pasireotide shows potential in carcinoid tumors, acromegaly, Cushing's disease

May 5, 2006

Eltrombopag induces responses in hepatitis C patients with thrombocytopenia

May 5, 2006

Mount Sinai researchers identify important regulator of postmenopausal bone loss

May 4, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...